Global Efforts & Resources in Parkinson’s Research

Emerging evidence shows that alpha-synuclein seed amplification assays (SAAs) have the potential to differentiate people with Parkinson's disease from healthy controls.

Since 2000, MJFF has been at the forefront of major scientific breakthroughs; investing $1.75B in research and providing open source data and resources to the researcher community.

MJFF provides Parkinson’s Disease landscape reports to the researcher community including a target report, biomarker report, and clinical pipeline report - highlighting the latest advancements in therapeutic development.

+ Parkinson's Disease Target Report: This report includes profiles of emerging and advanced targets along with a summary of the current status of the target as it relates to therapeutic development, its connection to Parkinson's disease, MJFF’s investments to date, and companies working on the respective target.

+ Parkinson's Disease Biomarker Report: This report provides an overview of the Parkinson’s disease biomarkers landscape, with a focus on biochemical and molecular based assays that MJFF staff are currently monitoring. It is intended to reflect biomarkers at various stages of development and validation for the indicated intended uses (e.g., diagnosis, monitoring, etc.)

+ Parkinson's Disease Clinical Pipeline Report: This report provides an overview of therapies currently in clinical development for Parkinson’s disease. The program status and result information include updates until March 2023.

The study, a collaborative effort between multiple nonprofit partner organizations and industry sponsors, details the economic impact of Parkinson's disease in the U.S, including prevalence data as well as medical and non-medical costs associated with Parkinson's disease.

Much like Alzeihmer's and Huntington's, Parkinson‘s disease is moving towards a biologic staging system, with a potentially transformational impact on research.

The Parkinson’s Progression Markers Inititative (PPMI) is MJFF’s landmark longitudinal study. Launched in 2010, PPMI is collaborating with partners around the world to create a robust open-access data set and biosample library to speed scientific breakthroughs and new treatments.

The Global Parkinson’s Genetics Program (GP2) is an ambitious program to genotype >150,000 volunteers around the world to further understand the genetic architecture of Parkinson’s disease. MJFF is the implementing partner of the Aligning Sciences Across Parkinson's (ASAP) initiative, of which GP2 is a resource program.